{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+condition",
    "query": {
      "intervention": "Treatment condition"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 28481,
    "total_pages": 2849,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+condition&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T17:37:37.083Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00464698",
      "title": "Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obsessive Compulsive Disorder"
      ],
      "interventions": [
        {
          "name": "Duloxetine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2005-12",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-09-03T17:37:37.083Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00464698"
    },
    {
      "nct_id": "NCT03904498",
      "title": "COMT Inhibition Among Individuals With Comorbid AUD/ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Use Disorder",
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Tolcapone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 23,
      "start_date": "2021-08-16",
      "completion_date": "2026-03-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-09-03T17:37:37.083Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03904498"
    },
    {
      "nct_id": "NCT01164163",
      "title": "INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "ruxolitinib phosphate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 49,
      "start_date": "2010-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-10-23",
      "last_synced_at": "2026-09-03T17:37:37.083Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01164163"
    },
    {
      "nct_id": "NCT00701298",
      "title": "Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "peginterferon alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "decitabine",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2009-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-02-24",
      "last_synced_at": "2026-09-03T17:37:37.083Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00701298"
    },
    {
      "nct_id": "NCT00411398",
      "title": "A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "General Anxiety Disorder, Social Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Namenda/Memantine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "State University of New York - Upstate Medical University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 15,
      "start_date": "2006-12",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2014-12-10",
      "last_synced_at": "2026-09-03T17:37:37.083Z",
      "location_count": 1,
      "location_summary": "Syracuse, New York",
      "locations": [
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00411398"
    },
    {
      "nct_id": "NCT05228132",
      "title": "The Pristine Post-Market Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Kidney Failure, Chronic",
        "Hemodialysis Complication",
        "Hemodialysis Catheter Infection",
        "Hemodialysis Access Failure",
        "Central Venous Catheter Related Bloodstream Infection",
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Pristine™ Long-Term Hemodialysis Catheter",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "C. R. Bard",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 142,
      "start_date": "2022-05-16",
      "completion_date": "2022-09-21",
      "has_results": true,
      "last_update_posted_date": "2024-04-11",
      "last_synced_at": "2026-09-03T17:37:37.083Z",
      "location_count": 6,
      "location_summary": "Dothan, Alabama • New Haven, Connecticut • Shreveport, Louisiana + 3 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05228132"
    },
    {
      "nct_id": "NCT02252198",
      "title": "Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Epistem Genedrive® and MolBio Truenat™",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 504,
      "start_date": "2014-02",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2017-12-12",
      "last_synced_at": "2026-09-03T17:37:37.083Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02252198"
    },
    {
      "nct_id": "NCT02675998",
      "title": "An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperphosphatemia"
      ],
      "interventions": [
        {
          "name": "Tenapanor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ardelyx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 219,
      "start_date": "2016-01",
      "completion_date": "2018-01-17",
      "has_results": true,
      "last_update_posted_date": "2020-08-10",
      "last_synced_at": "2026-09-03T17:37:37.083Z",
      "location_count": 32,
      "location_summary": "Huntsville, Alabama • Riverside, California • Denver, Colorado + 28 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lauderdale Lakes",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02675998"
    },
    {
      "nct_id": "NCT01529463",
      "title": "Effect of Post Discharge Follow-up on Readmission Rates for Congestive Heart Failure Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Congestive Heart Failure",
        "Systolic Dysfunction"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Trinity Health Of New England",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2011-01",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2013-03-01",
      "last_synced_at": "2026-09-03T17:37:37.083Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01529463"
    },
    {
      "nct_id": "NCT01121263",
      "title": "Hybrid Revascularization Observational Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 298,
      "start_date": "2010-05",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2014-03-14",
      "last_synced_at": "2026-09-03T17:37:37.083Z",
      "location_count": 11,
      "location_summary": "Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 8 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01121263"
    }
  ]
}